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ABSTRACT
Wiskott-Aldrich syndrome (WAS) is an X-linked primary immunodeficiency disease with unique and character-
istic features. In 1994, the responsible gene for WAS, the WASP gene on X-chromosome, was identified. Since
then, renewed clinical and basic researches of WAS have started and remarkably developed. I will comment on
recent progress in the clinical and basic researches of WAS, including some topics reported by our and other
groups.
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INTRODUCTION
Wiskott-Aldrich syndrome (WAS) is an X-linked pri-
mary immunodeficiency disease (PID) characterized
clinically with the triad; immunodeficiency, bleeding
tendency with microthrombocytopenia and severe ec-
zema. An increased risk for autoimmune disorders
and lymphoid malignancies is another characteristic
clinical features. In 1937, Wiskott A., a German pedia-
trician, originally reported three brothers who pre-
sented shortly after birth with thrombocytopenia,
bloody diarrhea, eczema and recurrent ear infec-
tions.1 All the three brothers died less than 2 years
old of intestinal bleeding and sepsis. In 1954, Aldrich
R.A. and others reported six generations of the family
members, 1640 males but no females, died with
similar clinical features that described by Wiskott, in-
dicating the disease inherited as X-linked trait.2 Clini-
cal features and severity of WAS patients are highly
varied, resulting in difficult to make diagnosis in early
infancy especially for milder cases. Indeed, only one
third of the patients show all the triad. A break-
through in clinical and basic researches of WAS has
been started since 1994, when the responsible gene
for WAS, the WASP gene, was identified.3 WASP con-
sists of 12 exons, encodes a 502 amino-acid protein
expressing only in hematopoietic lineage cells, and
contains several unique domains corresponding to ac-
tin polymerization and signal transduction. Since
then, the definite diagnosis of WAS has been possible
for suspected cases, and researches of molecular
pathogenesis for WAS have started and remarkably
developed. In this review, I will comment on recent
progress in the clinical and basic researches of WAS,
including some topics reported by our and other
groups.
WAS IN PID CLASSIFICATION AND WAS
PHENOTYPES
WAS belongs to the category of “well defined syn-
dromes with immunodeficiency” in the latest classifi-
cation in the report from the international union of
immunological societies expert committee for pri-
mary immunodeficiencies.4 In the category, six sub-
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Table　1　Clinical phenotypes and associated with mutations of WASP
WAS XLT IXLT XLN
Phenotypes
Clinical scores 3, 4, 5A/M 1, 2, (5A/M)† <1 0
Thrombocytopenia + + -/+ -
Small platelets + + + -
Eczema + -/+ - -
Immunodefi ciency + -/(+) - +‡
Autoimmunity Frequent Possible† - -
Malignancy Frequent Possible† - -
WASP mutation Nonsense, Missense, 
Frame shift caused by 
small deletion/insertion, 
Splicing defects
Missense, Inframe 
small deletions/inser-
tions, Splicing defects
Missense Specifi c missense 
disrupting autoinhibi-
tion;
L270P, S272P 
and I294T
WASP expression Absent or truncated Reduced Normal quantity Normal quantity
†XLT patients may progress to clinical score 1 or 2 into 5 (A: autoimmunity, M: malignancy).
‡Immunodefi ciency in XLN patients results from severe neutoropenia, different from immunodefi ciency in WAS.
classified groups are included with common key
words such as DNA repair defects, thymic defects
and so on. WAS is the only disease in one sub-
classified group without the key words, thus, WAS is
a unique PID.
Clinical features and severity of WAS patients are
highly varied resulting from the type of mutations in
WASP gene. X-linked thrombocytopenia (XLT), hav-
ing been presumed a variant disease of WAS with iso-
lated thrombocytopenia sometimes associated mild
eczema, was turned out to be caused by mutation in
WASP, confirming that XLT and WAS are allelic dis-
eases.5 The scoring system (0 to 5) to define clinical
phenotype associated withWASP gene mutations was
proposed.6 Based on the score, we can predict the
prognosis, thus provide an appropriate therapy for
each patient.7 Recently, X-linked severe congenital
neutropenia (XLN), totally different clinical features
from WASXLT, was revealed being caused by gain
of function-mutations of WASP.8 Then, XLN was
added to the scoring system as “0”, although it looks
incongruity presenting there. Clinical phenotypes as-
sociated with mutations of WASP gene are shown in
Table 1.
WASP; STRUCTURE, FUNCTION AND MU-
TATIONS
WASP is a member of a family of proteins involved in
signaling and cytoskeletal organization that includes
N-WASP and ScarWAVE.9,10 WASP plays a critical
role in linking cellular signals that activate Cdc42 to
the actin cytoskeleton. WASP possesses an Ena-Vasp
homology domain 1 (EVH1), also referred to as a
WASP homology domain 1 (WH1), a short basic re-
gion (BR), a Cdc42Rac GTPase binding domain
(GBD), a proline-rich region (PRR), a G-actin-binding
verprolin homology (V) domain, a cofilin homology
(C) domain and a C-terminal acidic (A) segment (Fig.
1a). In resting cells, WASP exists in an autoinhibited
inactive state and WASP interacting protein (WIP)
binds to the EVH1 domain and stabilizes WASP.11
Many signals that activate WASP to relieve this auto-
inhibition: these include binding of Cdc42 to the GBD
domain, phosphorylation, and binding of SH3 do-
mains containing proteins (such as Nck) to the
proline-rich region. Disruption of the autoinhibited
conformation enables actin related protein (Arp) 23
binding and actin polymerization (Fig. 1b).
Approximately 300 different mutations in WASP
have been reported. Those mutations are distributed
throughout all area in the gene, but clustering in the
first 4 exons and exons 7 and 10. Then, analyzing a
large number of patients with WASXLAXLN has
made us possible to establish a strong association of
genotype-phenotype relation.12-15 Mutations for WAS
are various, but patients with WAS show lack or
sparse of WASP in the cells. Common mutations for
XLT are missense mutations in exons 1-2 or splice
site mutations, those result in reducing but remaining
WASP level. In contrast, mutations for XLN are
unique; thus far, only three missense WASP muta-
tions; L270p, S272P and I294T have been identified.16
All the three mutations are gain-of function types,
which lead to disrupt the hydrophobic fold, loss of
the auto-inhibited structure of inactive WASP, and
constitutive availability of the carboxy-terminal VCA-
segment for actin-polymerization.
CLINICAL FEATURES
The triad of WAS, susceptibility to infection due to
various immunodeficiency, bleeding tendency with
micro-thrombocytopenia and severe eczema, is fa-
mous clinical features. However, it would be neces-
sary to notice that only one third of WAS patients rep-
Recent Progress in WAS Researches
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Fig.　1　WASP structure and function. a. Inactive form of WASP. b. Active form of 
WASP. The VCA domain is bound to the BGD to form an autoinhibitory conforma-
tion. Activation of WASP by CDC42 or phosphorylation of tylosin291 relieves the 
inactive to the activate form. Disruption of the autoinhibited conformation enables 
Arp 2/3 binding and actin polymerization. EVH1, Ena-Vasp homology domain 1; 
WH1, WASP homology domain 1; BR, basic region; GBD, a Cdc42/Rac GTPase 
binding domain; PRR, a proline-rich region; V, verprolin homology domain; C, co-
fi lin homology domain; A, acidic segment; WIP, WASP interacting protein.
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resent the triad especially during their infancy. Older
WAS patients reveal an increased risk for autoim-
mune disorders and lymphoid malignancies, that is
another characteristic clinical features.
DEFECTS OF IMMUNE SYSTEM
WAS patients with the clinical score more than 3
show high susceptibility to various pathogens. Main
pathogens involved are herpes viruses, some bacteria
including capsule forming such pneumococcus, fun-
gus, pneumocystis jeroveci and others. Defects of im-
mune system in WAS are complicated and various.
Since WASP is expressed exclusively in hematopoie-
tic cells, and is a key molecule of the actin polymeri-
zation and actin-regulating signals, defective immu-
nological function is observed in most immune cell
lineages including T cells, B cells, monocytesmacro-
phagesdendritic cells (DCs), and granulocytes. The
defects are based on impaired cell migration and cy-
toskeletal rearrangement, those affects immune cell
effector function and immunological synapse forma-
tion. Some typical cases of WAS show low IgM, high
IgA and IgE, albeit exceptional cases are also ob-
served. Antibody responses to polysaccharide anti-
gen would be reduced in some cases including low
isohemagglutinin titers. Peripheral blood lymphocyte
number often decreases over time, especially CD4+
and CD8+ T cells due to accelerated cell death due to
spontaneous apoptosis resulting from attenuated ex-
pression of Bcl-2.17 Poor proliferation responses to
immobilized anti-CD3, mimicking stimulation thro-
ugh T cell receptors, are commonly observed.
PLATELET ABNORMALITIES
Bleeding such as bloody diarrhea, epistaxis, purpura,
intracranial hemorrhage due to thrombocytopenia is
most commonly observed clinical manifestations. Be-
cause platelet associated IgG is detected in some
cases, such WAS patients are sometimes misdiag-
nosed and mistreated as immune thrombocytopenic
purpura (ITP). In this sense, evaluation of platelet vol-
ume would be important for the correct diagnosis of
WAS; microthrombocyte in WAS versus large to nor-
mal size thrombocyte in ITP. Although an intrinsic
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Fig.　2　Severe atopic like eczema in a patient with WAS. 
Male infant with WAS representing severe atopic like derma-
titis with petechial hemorrhage.
platelet defect related to abnormal WASP, such as ab-
normal thrombopoietin (TPO) signaling, is pro-
posed,18 production of platelets is normal in most
WAS patients. Destruction of platelets in spleen is
considered as major mechanism of thrombocytopenia
in WAS, because WAS patients receiving splenec-
tomy show correction of platelet number and size.19
ECZEMA
Eczema develops in 80% of WAS patients (Fig. 2).12
Eczema varies in severity and persistence, and some-
times shows poor response to the standard therapy
for eczema. Topical tacrolimus would be effective in
some WAS patients with severe eczema.20 The patho-
genesis of eczema in WAS remains unknown, how-
ever, the similar basis for atopic dermatitis could be
considered, because high level of IgE and imbal-
anced cytokine production patterns (Th1 < Th2) are
generally observed in patients with WAS.21
AUTOIMMUNE DISEASES
WAS patients frequently (40-70%) develop autoim-
mune diseases.22,23 The onset age is less than 2 years
in most cases, however, some autoimmune manifesta-
tions may develop later. The most common complica-
tions reported are autoimmune hemolytic anemia,
neutropenia and thrombocytopenia (autoimmune
type), cutaneous vasculitis, arthritis, nephritis24 and
inflammatory bowel diseases. Although less fre-
quently, XLT patients also develop the similar autoim-
mune complications.7 In those cases of XLT, the clini-
cal score of 1 or 2 will progress into 5(A). The precise
mechanism of autoimmunity has not fully been un-
derstood. Since WASP is committed to various im-
mune cell (T cells, B cells, NK cells, DCs) functions,
dysfunction of WASP may destabilize pivotal mecha-
nisms participating in the maintenance of immune tol-
erance. Recent studies indicated that WAS patients
have the defective peripheral tolerance due to dys-
functional WASP-defective regulatory T cells
(Tregs).25
MALIGNANCIES
Malignant diseases, mainly lymphoreticular type
such as lymphoma, leukemia, myelodysplasia, are ob-
served in 10-20% of WAS patients.12,23 We also re-
ported a fatal case of Epstein-Barr virus associated
lymphoproliferative disorder (EBV-LPD).26 Malignan-
cies can develop during early in childhood, but after
their adolescence in most cases. Immunodeficiency is
prone to malignant diseases, however, the basis for
high incidence of malignancy in WAS has not yet
been clarified. Impaired function of cytotoxic T cells
and NK cells, observed in WAS patients may in part
contribute to high incidence of malignancies. The in-
cidence of malignancies in XLT patients is lower than
that of WAS patients, but still significant. Further-
more, it is to note that patients with some specific
WASP mutation [the introns 6 (+5), g to a], although
their immune defects seemed to be mild, showed
high incidence (44%) of lymphoma.27 Thus, the
mechanisms of oncogenesis in WAS patients are
thought to be complex and multi-factorial.
DIAGNOSIS
Since a clinical feature and severity of WAS patients
are highly varied, the diagnosis of WAS for atypical
cases has been clinically difficult. In 1994, the respon-
sible gene for WAS; WASP gene, was identified.3
Since then, the definite diagnosis of WAS has been
possible by detection of mutations in the gene. We
established the method to evaluate the intracellular
WASP level using flow cytometory, and applied it for
making diagnosis of WAS patients and carriers (Fig.
3).28,29 It is to note that WAS-carriers usually show no
WASP-negative lymphocytes, but their monocytes
consist of a small portion of WASP-negative cells be-
sides a large potion of WASP-positive cells, indicating
that WASP-dependency for growth and development
would be different among hematopoietic cell line-
ages. Some patients, especially male infants sus-
pected to have immune thrombocytopenic purpura
(ITP), should be considered the possible diagnosis of
WAS. Because typical symptoms may not yet occur in
WAS patients during infancy. We also reported that
Recent Progress in WAS Researches
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Fig.　3　Flow cytometric analysis of the intracellular WASP level. Intracellular WASP expression was analyzed by fl ow cy-
tometory using anti-WASP antibody 3F3A5. Lymphocytes and monocytes populations were independently evaluated. No 
WASP-positive lymphocytes or monocytes was detected in the WAS patient. No WASP-negative lymphocytes, but small 
portion of WASP-negative monocytes (white arrow) were detected in the WAS carrier. Red line indicates results using a con-
trol antibody.
Healthy WAS patient
monocytes
lymphocytes
WAS carrier
Anti-WASP antibody: 3F3A5
screening by flow cytometry for WASP was recom-
mended for boys with persistent thrombocytopenia of
an unknown etiology for excluding and confirming
the WAS diagnosis.30
REVERSION OF INHERITED MUTATIONS
There are various types of somatic mosaicism re-
ported in patients with genetic and non-genetic dis-
eases.31 Among them, somatic mosaicism due to re-
version to normal of inherited mutations sometimes
occur in patients with various PID including adeno-
sine deaminase (ADA) deficiency, X-linked severe
combined immunodeficiency (X-SCID) and WAS,
some of them show atypically mild clinical pheno-
types. We also reported such cases with ADA defi-
ciency32 and WAS.33,34 Basis for this phenomenon is
thought that a cell making reversion to normal of in-
herited mutation acquires normal function and “selec-
tive advantage”, thus expanding its population in vivo
to be detected. Now it is well known that this phe-
nomenon is commonly observed in WAS patients.
TREATMENT OF WASXLT
Supportive and prophylactic care for the complica-
tions including infectious diseases, bleeding, autoim-
mune diseases and malignancies, those are fre-
quently observed in WASXLT patients, is very im-
portant. Those include intravenous immunoglobulin
replacement, acyclovir for herpes virus, trimeth-
oprim-sulfamethoxazole for Pneumocystis jiroveci, ju-
dicious platelet transfusion for bleeding episodes, and
so on. Splenectomy to prevent serious bleeding com-
plications is controversial, because it could be effec-
tive to increase platelet number, however, the risks of
severe bacterial infections will be increased. To date,
therefore, splenectomy is not recommended at least
for patients planning to receive hematopoietic stem
cell transplantation (HST).
Recently, several group reported the results of
HST for patients with WAS, including our group.35,36
Overall 5-year survival is good as approximately 80-
90%, however, the results vary depending on recipi-
ent’s conditions (clinical score, age, complication,
etc.), types of donor source and conditioning regi-
mens. Evaluation of the chimerism status after HST is
important, because it is associated with an increased
risk of incomplete reconstitution and post-HST auto-
immunity.35 In fact, we observed various mixed chi-
merism status in WAS patients after HST by flow cy-
tometoric analysis, and found that the residual recipi-
ent cells were most consistently in the monocyte
population.37 To avoid the mixed chimerism status,
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myeloablative conditioning is recommended for WAS
patient in good condition at present, although less
toxic conditioning should be considered in the near
future. As for XLT patients, indication of HST is con-
troversial, however, some cases received HST from
suitable donor with good sequel. Considering autoim-
mune diseases or malignancies could be complicated
in some XLT patients, one might consider the indica-
tion of HST for XLT more positively.
WAS has been considered as a good candidate for
gene therapy, because we can use the same strategy
of hematopoietic stem cell gene therapy that used for
ADA deficiency and X-SCID. Furthermore, given
many reversion cases of WAS as a presumptive evi-
dence, gene introduced cells are expected to show
selective growth advantage in vivo, which is a key
condition for success of the gene therapy at present.
Recently, stem cell gene therapy was successfully re-
ported in two WAS patients,38 however, it is notewor-
thy that a leukemic event occurred in one of the
treated children, with LTR-mediated LMO2 gene
transactivation as a consequence of insertion in that
locus.39 This serious adverse event was just the same
as those observed in the stem cell gene therapy for X-
SCID patients. Thus, safety stem cell gene therapy
for WAS is still underway to be established.
CONCLUSION
In this review, I made a comment on the recent pro-
gress in the clinical and basic researches of WAS. Al-
though the remarkable advance has been made in
the fields of WAS researches, there are still various
unsolved subjects to be confronted us.
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